Financial Performance - Revenue rose by 28.2% to approximately $268.8 million for the year ending December 31, 2024, up from approximately $209.6 million for the year ending December 31, 2023[4] - Gross profit increased by 28.7% to approximately $168.2 million for the year ending December 31, 2024, with a gross margin of approximately 62.6%[4] - Net profit grew by 46.6% to approximately $10.0 million for the year ending December 31, 2024, compared to approximately $6.8 million for the year ending December 31, 2023[5] - The adjusted net profit for the year ending December 31, 2024, was approximately $26.9 million, compared to approximately $26.1 million for the previous year[5] - The company reported a total operating profit of $6.28 million for 2024, compared to a loss of $3.93 million in 2023[58] - The basic and diluted earnings per share for the year ended December 31, 2024, were both $0.07, up from $0.04 in 2023[59] - The company’s profit attributable to owners for the year ended December 31, 2024, was $12,114,000, an increase of 60.5% from $7,530,000 in 2023[86] Market Expansion - Revenue from markets outside of China surged by 290.4% to approximately $80.5 million, accounting for 30.0% of total revenue[4] - The number of completed cases in markets outside of China skyrocketed by 326.4% to approximately 140,700 cases, representing 39.1% of total completed cases[4] - The company plans to expand its global market presence, including establishing new manufacturing facilities in the U.S. and increasing support capabilities in Brazil[19] Product Development - The company launched the "KiD Max" and "KiD Anti-Cavity" product lines, expanding its pediatric product matrix to address oral health issues for children and adolescents[11] - Investment in research and development reached approximately $21.3 million in 2024, accounting for 7.9% of total revenue, with 241 patents and 22 software copyrights registered[12] - The company is focusing on innovation in key materials, product design, and software algorithms, with several research papers published in top international journals[14] Operational Efficiency - The company aims to enhance operational efficiency through further digitization of its systems and improve user experience in medical services[19] - Total costs increased by 27.4% from approximately $78.9 million for the year ended December 31, 2023, to approximately $100.6 million for the year ended December 31, 2024, primarily due to global business expansion[20] - Administrative expenses rose by 16.2% from approximately $39.8 million for the year ended December 31, 2023, to approximately $46.2 million for the year ended December 31, 2024, reflecting improved operational efficiency[23] Cash Flow and Assets - Cash and cash equivalents and term deposits totaled approximately $339.1 million as of December 31, 2024, down from approximately $379.7 million as of December 31, 2023[34] - Non-current assets increased to $186.44 million in 2024, up from $146.53 million in 2023, reflecting a growth of 27.19%[61] - The company reported a net cash outflow from investing activities of $138.83 million, similar to the $138.76 million in 2023[66] Shareholder Returns - The company plans to pay a special final dividend of HKD 0.38 per share for the year ending December 31, 2024[5] - The proposed special final dividend is HKD 0.38 per share, subject to approval at the annual general meeting[132] Corporate Governance - The company has adopted the corporate governance code and has complied with all applicable provisions during the reporting period[127] - The audit committee, consisting of three independent non-executive directors, has reviewed the group's annual performance for the year ending December 31, 2024, and recommended approval to the board[135] Employee and Management - Employee costs for the year ending December 31, 2024, are approximately USD 141.5 million[121] - Key management compensation totaled $8,588,000 for the year ending December 31, 2024, compared to $7,315,000 in 2023, reflecting an increase of 17.4%[114] - The company has 3,576 employees as of December 31, 2024[121]
时代天使(06699) - 2024 - 年度业绩